Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma: early-phase trial registry
167 of 441 indexed Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11 of 28,963 conditions by registered trial count.
441 US clinical trials · 167 currently recruiting · #11 of 28,963 conditions by registered trial count
Multiple Myeloma: 441 US clinical trials tracked, 167 recruiting.
Multiple Myeloma is the subject of 441 registered US clinical trials on ClinicalTrials.gov, 167 of them currently open to new participants. 52 are in Phase 3-4 (later-stage) and 298 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Open enrollment, early-phase tilt
Multiple Myeloma has 441 registered US clinical trials, 167 of them open to new participants right now, about 38% of the total.
- 167
- recruiting participants now
- 38%
- of trials open to enrollment
- 52
- in Phase 3-4 (later-stage)
- 34
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #11 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma recruits in line with its size-band peers.
167 of 441 indexed trials (37.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 441 trials (7.7%). 154 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Myeloma enrolment sits around 65 participants.
Median target enrolment is 65 among the 439 trials that report a genuine target (sentinel values excluded). 262 of those (59.7%) plan for fewer than 100 participants.
-
Multiple Myeloma research is mostly interventional.
386 interventional and 55 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
441 total, page 5 of 9
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT03933735
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Janssen Research & Development
NCT04133636
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
NCT04126200
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
NCT05831358
COVID19 OutcomeS in Myeloma and the Impact of VaCcines
ASH Research Collaborative
NCT05831787
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
All4Cure
NCT05673083
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Janssen Research & Development
NCT03901963
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
NCT04649359
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
University of Chicago
NCT02659293
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
BioLineRx
NCT03246529
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline
NCT05064358
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
NCT00572169
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Janssen Research & Development
NCT05050097
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
NCT03844048
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT03314181
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
NCT06163898
Biomarker for Infection Risk in CLL and MM
Massachusetts General Hospital
NCT05844033
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
NCT03173092
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Janssen Research & Development
NCT04722146
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Kite, A Gilead Company
NCT05396885
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Genentech
NCT04910568
Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
Massachusetts General Hospital
NCT06073353
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
NCT02899052
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
GlaxoSmithKline
NCT04091126
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
NCT07084896
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
CARsgen Therapeutics Co.
NCT03915184
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Poseida Therapeutics
NCT03741127
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT04184050
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems
NCT05587972
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
Memorial Sloan Kettering Cancer Center
NCT04497961
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
NCT00869232
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Hoffmann-La Roche
NCT05535244
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Thomas Martin, MD
NCT02332850
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT01746849
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
University of Alabama at Birmingham
NCT05434689
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Celgene
NCT06045806
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
NCT03500445
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT03290950
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Weill Medical College of Cornell University
NCT01559935
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
NCT04782687
Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics
NCT05308225
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
NCT06169215
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
NCT05271630
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
NCT00378105
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
NCT02719613
DARA RVD For High Risk SMM
Omar Nadeem, MD
NCT04775550
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
University of Michigan Rogel Cancer Center
NCT04140162
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
University of Chicago
NCT04108624
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 142 |
| Phase 3 | 45 |
| Phase 4 | 7 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Multiple Myeloma right now
167 recruiting of 441 indexed (38% open).
Phase mix: 52 late (III/IV) vs 298 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (34 trials), 9 others listed. 50 shown below, recruiting first. #11 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Multiple Myeloma?
PlainTrial tracks 441 US clinical trials for Multiple Myeloma, of which 167 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Multiple Myeloma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.